According to a report by the Oxford Vaccine Group, the two doses of the AstraZeneca vaccine administered 44-45 weeks apart can generate nearly four times the level of COVID-19 antibodies than when the doses were given 8-12 weeks apart.
Moreover, the volunteers for the coronavirus vaccine who received their second dose 15-25 weeks after the first, saw average antibody levels at nearly twice those in the 8-12 week interval. This pointed to the fact that lengthening the duration between doses appeared to be boosting antibody count.
Furthermore, the average IgG (immunoglobulin G) levels for 8-12, 15-25, and 44-46 weeks were 923, 1860 and 3738 units respectively, when measured 28 days after the second dose. The volunteers chosen were among those who'd been part of the phase 1/2 and phase 2/3 clinical trials.
On the other hand, the COVID-19 vaccine by Johnson and Johnson will reportedly not be undertaking local trials for its vaccine in India. According to reports, while the US-based pharmaceuticals company had sought approval for conducting bridging trials in the country, it would not have to do the same now since India has changed that requirement. Moreover, the company has stated that it is exploring how to ramp up the availability of its vaccine in India.
ALSO READ: Oxford study says, mixing COVID-19 vaccines could generate robust immune response
Share
Tweet
